181P Poor response to PD-1 inhibitors in metastatic non-small cell lung cancer (mNSCLC) patients with liver metastases may be mediated by myeloid populations

M Makarem,S.C Lau,M.J Elliott,A Rabinovitch,S Kuang,S Schmid,M.S Tsao,T Mcgaha,P Ohashi,F.A Shepherd,P Bradbury,G Liu,N.B Leighl,A Sacher

doi:10.1016/j.annonc.2021.10.201

181P Poor response to PD-1 inhibitors in metastatic non-small cell lung cancer (mNSCLC) patients with liver metastases may be mediated by myeloid populations

M Makarem, S.C Lau + Show 12 more

Open Access

https://doi.org/10.1016/j.annonc.2021.10.201

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Dec 1, 2021
License type: publisher-specific-oa

Affiliation: Princess Margaret Cancer Centre, University Health Network, University of Toronto

#Myeloid Populations #Metastatic Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Liver metastases (LM) in patients with mNSCLC are associated with poor clinical outcomes. The liver possesses a tolerogenic microenvironment maintained by myeloid cell populations which may contribute to poor response to PD1 inhibitors (PD-1i). We hypothesized that the presence of LM may associate with a myeloid-predominant state in patients treated with PD-1i.

Full Text